334 related articles for article (PubMed ID: 26938947)
1. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors.
Eom HS; Choi BK; Lee Y; Lee H; Yun T; Kim YH; Lee JJ; Kwon BS
J Immunother; 2016 Apr; 39(3):140-8. PubMed ID: 26938947
[TBL] [Abstract][Full Text] [Related]
2. 4-1BB-based isolation and expansion of CD8+ T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy.
Choi BK; Lee SC; Lee MJ; Kim YH; Kim YW; Ryu KW; Lee JH; Shin SM; Lee SH; Suzuki S; Oh HS; Kim CH; Lee DG; Hwang SH; Yu EM; Lee IO; Kwon BS
J Immunother; 2014 May; 37(4):225-36. PubMed ID: 24714356
[TBL] [Abstract][Full Text] [Related]
3. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
Taylor GS; Jia H; Harrington K; Lee LW; Turner J; Ladell K; Price DA; Tanday M; Matthews J; Roberts C; Edwards C; McGuigan L; Hartley A; Wilson S; Hui EP; Chan AT; Rickinson AB; Steven NM
Clin Cancer Res; 2014 Oct; 20(19):5009-22. PubMed ID: 25124688
[TBL] [Abstract][Full Text] [Related]
4. Non-uniform
Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
Front Immunol; 2019; 10():2489. PubMed ID: 31736946
[TBL] [Abstract][Full Text] [Related]
5. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Morishima S; Nakamura S; Yamamoto K; Miyauchi H; Kagami Y; Kinoshita T; Onoda H; Yatabe Y; Ito M; Miyamura K; Nagai H; Moritani S; Sugiura I; Tsushita K; Mihara H; Ohbayashi K; Iba S; Emi N; Okamoto M; Iwata S; Kimura H; Kuzushima K; Morishima Y
Leuk Lymphoma; 2015 Apr; 56(4):1072-8. PubMed ID: 24975317
[TBL] [Abstract][Full Text] [Related]
6. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
[TBL] [Abstract][Full Text] [Related]
7. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
8. Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.
Zheng Y; Parsonage G; Zhuang X; Machado LR; James CH; Salman A; Searle PF; Hui EP; Chan AT; Lee SP
Cancer Immunol Res; 2015 Oct; 3(10):1138-47. PubMed ID: 25711537
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
10. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
McLaughlin LP; Gottschalk S; Rooney CM; Bollard CM
Methods Mol Biol; 2017; 1532():255-265. PubMed ID: 27873282
[TBL] [Abstract][Full Text] [Related]
11. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
13. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.
Klatt T; Ouyang Q; Flad T; Koetter I; Bühring HJ; Kalbacher H; Pawelec G; Müller CA
J Rheumatol; 2005 Feb; 32(2):239-51. PubMed ID: 15693083
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
15. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.
Fox CP; Haigh TA; Taylor GS; Long HM; Lee SP; Shannon-Lowe C; O'Connor S; Bollard CM; Iqbal J; Chan WC; Rickinson AB; Bell AI; Rowe M
Blood; 2010 Nov; 116(19):3695-704. PubMed ID: 20671118
[TBL] [Abstract][Full Text] [Related]
16. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
17. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
[TBL] [Abstract][Full Text] [Related]
18. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
Fogg MH; Wirth LJ; Posner M; Wang F
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3318-23. PubMed ID: 19211798
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas.
Cho HI; Hong YS; Lee MA; Kim EK; Yoon SH; Kim CC; Kim TG
Int J Hematol; 2006 Jan; 83(1):66-73. PubMed ID: 16443556
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
